 |
Intermittent Claudication
|
||
cilostazol - Pletal ®
|
||
|
MOA: Antiplatelet agent. Phosphodiesterase III
inhibitor => increased cyclic AMP => inhibition of platelet aggregation
and vasodilation. Other effects of phosphodiesterase III inhibition
include increased cardiac contractility, accelerated AV nodal
conduction, increased ventricular automaticity, heart rate, and coronary
blood flow. Dosing (Adults): Peripheral vascular disease: 100 mg orally twice daily taken at least 30 minutes before or 2 hours after breakfast and dinner. Dosage should be reduced to 50 mg twice daily during concurrent therapy with inhibitors of CYP3A4 or CYP2C19. Supplied: 50 mg, 100 mg tablet. |
||
pentoxifylline - Trental ®
|
||
|
MOA: Reduces blood viscosity via increased leukocyte
and erythrocyte deformability and decreased neutrophil
adhesion/activation. Improves peripheral tissue oxygenation presumably
through enhanced blood flow. Dosing (Adults): Peripheral vascular disease: 400 mg orally 3 times/day with meals. Maximal therapeutic benefit may take 2-4 weeks to develop. Recommended to maintain therapy for at least 8 weeks. May reduce to 400 mg twice daily if GI or CNS side effects occur. Supplied: 400 mg extended release tablet. |
||
Disclaimer |
||
|
Listed dosages are for - Adult patients ONLY. PLEASE READ THE
DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
GlobalRPH does not directly or indirectly practice medicine or provide
medical services and therefore assumes no liability whatsoever of any
kind for the information and data accessed through the Service or for
any diagnosis or treatment made in reliance thereon. David F. McAuley, Pharm.D., R.Ph. GlobalRPh Inc. |
| Disclaimer Contact Us Privacy Policy Website Search | We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc. |
 |
 |